Lindsey Shapiro is a science writer for ALS News Today with a PhD in neuroscience. She covers the latest news and information on a variety of amyotrophic lateral sclerosis topics.| ALS News Today
About 90% of cases of amyotrophic lateral sclerosis (ALS) are characterized as sporadic ALS, meaning they occur spontaneously.| ALS News Today
Qalsody (tofersen) is conditionally approved in the U.S. as treatment for amyotrophic lateral sclerosis associated with SOD1 gene mutations.| ALS News Today
Marisa Wexler is a senior science writer for ALS News Today with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of amyotrophic lateral sclerosis topics.| ALS News Today
Category archive page for News.| ALS News Today
FDA approved Qalsody (tofersen) to treat patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene (SOD1-ALS). Qalsody is an antisense oligonucleotide that targets SOD1 mRNA to reduce the synthesis of SOD1 protein. The approval was based o| U.S. Food and Drug Administration
ALS is a progressive neurological disorder that damages motor neurons. Learn more about types, causes, symptoms, diagnosis, and treatment.| ALS News Today
